Co-Diagnostics files 1-for-30 reverse stock split to regain Nasdaq minimum bid price compliance

Co-Diagnostics, Inc.

Reverse stock split ratio set at 1-for-30; effective January 2, 2026 at 12:01 a.m. ET.
Approximately 2,095,031 shares outstanding post-split; new CUSIP 189763204; ticker CODX unchanged.
Fractional shares rounded up to next whole share; no fractional shares issued.
Split intended to enable compliance with Nasdaq $1.00 minimum bid price listing requirement.
Board approved ratio on Dec 29, 2025; stockholders authorized up to 1-for-30 at Dec 5 special meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.